{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T08:49:34Z","timestamp":1787302174311,"version":"build-2736575974"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T00:00:00Z","timestamp":1727481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T00:00:00Z","timestamp":1727481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100013703","name":"Royal Osteoporosis Society","doi-asserted-by":"publisher","award":["191"],"award-info":[{"award-number":["191"]}],"id":[{"id":"10.13039\/501100013703","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Fibroblast Growth Factor (FGF) receptor signalling is important for skeletal development. The FGF19 subfamily which includes FGF19 and FGF21 are involved in bone metabolism, although their effects on bone mineral density (BMD) and bone strength remain unclear. To further characterise the influence of these two factors on the skeleton, we studied the association between circulating concentrations of FGF19 and 21 with BMD and parameters of hip geometry and strength in post-menopausal osteoporosis (PMO). The study cohort consisted of 374 women aged (mean [SD]) 68.7[12.3] years with PMO. FGF19 and FGF21 were measured in serum by ELISA. BMD was measured at the lumbar spine (LS), total hip (TH) and femoral neck (FN) (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009277) by dual energy X-ray absorptiometry (DXA) and hip structural analysis (HSA) parameters (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009263) at the narrow neck of the femur (NN), Intertrochanter (IT) and Femoral shaft (FS) were derived from DXA scans. FGF19 and 21 were not associated with prevalent fractures or BMD when corrected for covariates; age, BMI, smoking habits and alcohol intake. Log-transformed FGF 21 was negatively associated with HSA parameters including Outer Diameter (OD) (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.019), Cross-sectional area (CSA) (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.01), cross-sectional moment of inertia (CSMI) (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.011), Section modulus (Z) (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.002) and cortical thickness (Co Th) (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.026) at the IT only. CSA, CSMI, Z and Co Th were significantly lower (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.05) in women with FGF21 concentrations greater than the median (&gt;\u2009103.5\u00a0pg\/ml). Our data suggest that FGF 21 may have potentially adverse effects on the skeleton. Further characterisation is needed, particularly as FGF 21 analogues or agonists may be used to treat obesity-related metabolic disorders.\n                  <\/jats:p>","DOI":"10.1007\/s00223-024-01284-3","type":"journal-article","created":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T14:02:41Z","timestamp":1727532161000},"page":"562-569","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effect of Fibroblast Growth Factor (FGF) 19 and 21 on Hip Geometry and Strength in Post-menopausal Osteoporosis (PMO)"],"prefix":"10.1007","volume":"115","author":[{"given":"EunJi","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia. E.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dwight","family":"Dulnoan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8465-5247","authenticated-orcid":false,"given":"Geeta","family":"Hampson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,28]]},"reference":[{"issue":"2","key":"1284_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s13105-019-00675-7","volume":"75","author":"K Dolegowska","year":"2019","unstructured":"Dolegowska K, Marchelek-Mysliwiec M, Nowosiad-Magda M, Slawinski M, Dolegowska B (2019) FGF19 subfamily members: FGF19 and FGF21. J Physiol Biochem 75(2):229\u2013240","journal-title":"J Physiol Biochem"},{"key":"1284_CR2","doi-asserted-by":"publisher","first-page":"267","DOI":"10.3389\/fendo.2018.00267","volume":"9","author":"RG Erben","year":"2018","unstructured":"Erben RG (2018) Physiological actions of fibroblast growth factor-23. Front Endocrinol 9:267","journal-title":"Front Endocrinol"},{"issue":"3","key":"1284_CR3","doi-asserted-by":"publisher","first-page":"e17868","DOI":"10.1371\/journal.pone.0017868","volume":"6","author":"AL Wu","year":"2011","unstructured":"Wu AL, Coulter S, Liddle C, Wong A, Eastham-Anderson J, French DM et al (2011) FGF19 regulates cell proliferation, glucose and bile acid metabolism via FGFR4-dependent and independent pathways. PLoS ONE 6(3):e17868","journal-title":"PLoS ONE"},{"key":"1284_CR4","doi-asserted-by":"publisher","first-page":"802541","DOI":"10.3389\/fendo.2021.802541","volume":"12","author":"RA Spann","year":"2021","unstructured":"Spann RA, Morrison CD, den Hartigh LJ (2021) The nuanced metabolic functions of endogenous FGF21 depend on the nature of the stimulus, tissue source, and experimental model. Front Endocrinol 12:802541","journal-title":"Front Endocrinol"},{"issue":"4","key":"1284_CR5","first-page":"390","volume":"41","author":"B Barutcuoglu","year":"2011","unstructured":"Barutcuoglu B et al (2011) Fibroblast growth factor-19 levels in type 2 diabetic patients with metabolic syndrome. Ann Clin Lab Sci 41(4):390\u2013396","journal-title":"Ann Clin Lab Sci"},{"issue":"8","key":"1284_CR6","doi-asserted-by":"publisher","first-page":"e13038","DOI":"10.1111\/obr.13038","volume":"21","author":"PM Ryan","year":"2020","unstructured":"Ryan PM et al (2020) Effect of bariatric surgery on circulating FGF-19: a systematic review and meta-analysis. Obes Rev 21(8):e13038","journal-title":"Obes Rev"},{"key":"1284_CR7","doi-asserted-by":"publisher","first-page":"655575","DOI":"10.3389\/fcvm.2021.655575","volume":"8","author":"J Yan","year":"2021","unstructured":"Yan J, Nie Y, Cao J, Luo M, Yan M, Chen Z, He B (2021) The roles and pharmacological effects of FGF21 in preventing aging-associated metabolic diseases. Front Cardiovasc Med 8:655575","journal-title":"Front Cardiovasc Med"},{"key":"1284_CR8","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1146\/annurev-pharmtox-032322-093904","volume":"63","author":"L Jin","year":"2023","unstructured":"Jin L, Yang R, Geng L, Xu A (2023) Fibroblast growth factor-based pharmacotherapies for the treatment of obesity-related metabolic complications. Annu Rev Pharmacol Toxicol 63:359\u2013382","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"11","key":"1284_CR9","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1056\/NEJMoa2304286","volume":"389","author":"R Loomba","year":"2023","unstructured":"Loomba R, Sanyal AJ, Kowdley KV, Bhatt DL, Alkhouri N, Frias JP et al (2023) Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH. N Engl J Med 389(11):998\u20131008","journal-title":"N Engl J Med"},{"issue":"1","key":"1284_CR10","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1053\/j.gastro.2020.08.004","volume":"160","author":"SA Harrison","year":"2021","unstructured":"Harrison SA, Neff G, Guy CD, Bashir MR, Paredes AH, Frias JP et al (2021) Efficacy and safety of aldafermin, an engineered FGF19 analog, in a randomized, double-blind, placebo-controlled trial of patients with nonalcoholic steatohepatitis. Gastroenterology 160(1):219\u2013231","journal-title":"Gastroenterology"},{"key":"1284_CR11","doi-asserted-by":"publisher","first-page":"14003","DOI":"10.1038\/boneres.2014.3","volume":"2","author":"N Su","year":"2014","unstructured":"Su N, Jin M, Chen L (2014) Role of FGF\/FGFR signaling in skeletal development and homeostasis: learning from mouse models. Bone Res 2:14003","journal-title":"Bone Res"},{"key":"1284_CR12","doi-asserted-by":"publisher","first-page":"118804","DOI":"10.1016\/j.lfs.2020.118804","volume":"265","author":"H Chen","year":"2021","unstructured":"Chen H, Li J, Zhang D, Zhou X, Xie J (2021) Role of the fibroblast growth factor 19 in the skeletal system. Life Sci 265:118804","journal-title":"Life Sci"},{"key":"1284_CR13","doi-asserted-by":"publisher","first-page":"112524","DOI":"10.1016\/j.biopha.2021.112524","volume":"146","author":"A Guo","year":"2022","unstructured":"Guo A, Li K, Tian HC, Tao BL, Xiao Q, Jiang DM (2022) FGF19 protects against obesity-induced bone loss by promoting osteogenic differentiation. Biomed Pharmacother 146:112524","journal-title":"Biomed Pharmacother"},{"key":"1284_CR14","doi-asserted-by":"publisher","first-page":"e1486","DOI":"10.6061\/clinics\/2020\/e1486","volume":"75","author":"YX Zhao","year":"2020","unstructured":"Zhao YX, Song YW, Zhang L, Zheng FJ, Wang XM, Zhuang XH et al (2020) Association between bile acid metabolism and bone mineral density in postmenopausal women. Clinics 75:e1486","journal-title":"Clinics"},{"issue":"4","key":"1284_CR15","doi-asserted-by":"publisher","first-page":"100548","DOI":"10.1016\/j.bj.2022.07.002","volume":"46","author":"Y Tang","year":"2023","unstructured":"Tang Y, Zhang M (2023) Fibroblast growth factor 21 and bone homeostasis. Biomed J 46(4):100548","journal-title":"Biomed J"},{"issue":"12","key":"1284_CR16","doi-asserted-by":"publisher","first-page":"3053","DOI":"10.1007\/s00198-013-2464-9","volume":"24","author":"P Lee","year":"2013","unstructured":"Lee P, Linderman J, Smith S, Brychta RJ, Perron R, Idelson C et al (2013) Fibroblast growth factor 21 (FGF21) and bone: is there a relationship in humans? Osteoporos Int 24(12):3053\u20133057","journal-title":"Osteoporos Int"},{"issue":"2","key":"1284_CR17","doi-asserted-by":"publisher","first-page":"273","DOI":"10.3803\/EnM.2018.33.2.273","volume":"33","author":"HS Choi","year":"2018","unstructured":"Choi HS, Lee HA, Kim SW, Cho EH (2018) Association between serum fibroblast growth factor 21 levels and bone mineral density in postmenopausal women. Endocrinol Metab 33(2):273\u2013277","journal-title":"Endocrinol Metab"},{"issue":"3","key":"1284_CR18","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s40618-020-01337-y","volume":"44","author":"DTW Lui","year":"2021","unstructured":"Lui DTW, Lee CH, Chau VWK, Fong CHY, Yeung KMY, Lam JKY et al (2021) Potential role of fibroblast growth factor 21 in the deterioration of bone quality in impaired glucose tolerance. J Endocrinol Invest 44(3):523\u2013530","journal-title":"J Endocrinol Invest"},{"key":"1284_CR19","doi-asserted-by":"publisher","first-page":"115630","DOI":"10.1016\/j.bone.2020.115630","volume":"141","author":"AE Moore","year":"2020","unstructured":"Moore AE, Kim E, Dulnoan D, Dolan AL, Voong K, Ahmad I et al (2020) Serum vitamin K(1) (phylloquinone) is associated with fracture risk and hip strength in post-menopausal osteoporosis: a cross-sectional study. Bone 141:115630","journal-title":"Bone"},{"issue":"2","key":"1284_CR20","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s11914-007-0002-4","volume":"5","author":"TJ Beck","year":"2007","unstructured":"Beck TJ (2007) Extending DXA beyond bone mineral density: understanding hip structure analysis. Curr Osteoporos Rep 5(2):49\u201355 (Epub 2007\/05\/25)","journal-title":"Curr Osteoporos Rep"},{"key":"1284_CR21","doi-asserted-by":"publisher","first-page":"601349","DOI":"10.3389\/fendo.2020.601349","volume":"11","author":"E Henriksson","year":"2020","unstructured":"Henriksson E, Andersen B (2020) FGF19 and FGF21 for the treatment of NASH-two sides of the same coin? Differential and overlapping effects of FGF19 and FGF21 from mice to human. Front Endocrinol 11:601349","journal-title":"Front Endocrinol"},{"issue":"8","key":"1284_CR22","doi-asserted-by":"publisher","first-page":"e72345","DOI":"10.1371\/journal.pone.0072345","volume":"8","author":"Y Hao","year":"2013","unstructured":"Hao Y, Zhou J, Zhou M, Ma X, Lu Z, Gao M et al (2013) Serum levels of fibroblast growth factor 19 are inversely associated with coronary artery disease in chinese individuals. PLoS ONE 8(8):e72345","journal-title":"PLoS ONE"},{"key":"1284_CR23","doi-asserted-by":"publisher","first-page":"830022","DOI":"10.3389\/fendo.2022.830022","volume":"13","author":"X Yu","year":"2022","unstructured":"Yu X, Xia Y, Jia J, Yuan G (2022) The role of fibroblast growth factor 19 subfamily in different populations suffering from osteoporosis. Front Endocrinol 13:830022","journal-title":"Front Endocrinol"},{"issue":"3","key":"1284_CR24","doi-asserted-by":"publisher","first-page":"345","DOI":"10.2169\/internalmedicine.3597-19","volume":"59","author":"S Yamamoto","year":"2020","unstructured":"Yamamoto S, Koyama D, Igarashi R, Maki T, Mizuno H, Furukawa Y, Kuro OM (2020) Serum endocrine fibroblast growth factors as potential biomarkers for chronic kidney disease and various metabolic dysfunctions in aged patients. Intern Med 59(3):345\u2013355","journal-title":"Intern Med"},{"issue":"6","key":"1284_CR25","doi-asserted-by":"publisher","first-page":"e0178580","DOI":"10.1371\/journal.pone.0178580","volume":"12","author":"Z Li","year":"2017","unstructured":"Li Z, Lin B, Lin G, Wu Y, Jie Y, Li X et al (2017) Circulating FGF19 closely correlates with bile acid synthesis and cholestasis in patients with primary biliary cirrhosis. PLoS ONE 12(6):e0178580","journal-title":"PLoS ONE"},{"issue":"6","key":"1284_CR26","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s00198-009-1056-1","volume":"21","author":"AZ LaCroix","year":"2010","unstructured":"LaCroix AZ, Beck TJ, Cauley JA, Lewis CE, Bassford T, Jackson R et al (2010) Hip structural geometry and incidence of hip fracture in postmenopausal women: what does it add to conventional bone mineral density? Osteoporos Int 21(6):919\u2013929 (Epub 2009\/09\/17)","journal-title":"Osteoporos Int"},{"key":"1284_CR27","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.bone.2015.04.001","volume":"77","author":"PK Fazeli","year":"2015","unstructured":"Fazeli PK, Faje AT, Cross EJ, Lee H, Rosen CJ, Bouxsein ML, Klibanski A (2015) Serum FGF-21 levels are associated with worsened radial trabecular bone microarchitecture and decreased radial bone strength in women with anorexia nervosa. Bone 77:6\u201311","journal-title":"Bone"},{"key":"1284_CR28","doi-asserted-by":"publisher","first-page":"4024877","DOI":"10.1155\/2023\/4024877","volume":"2023","author":"K Gawlik","year":"2023","unstructured":"Gawlik K, Milewicz T, Pawlica-Gosiewska D, Trznadel-Morawska I, Solnica B (2023) Fibroblast growth factor 21 in gestational diabetes mellitus and type 2 diabetes mellitus. J Diabetes Res 2023:4024877","journal-title":"J Diabetes Res"},{"issue":"3","key":"1284_CR29","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1177\/1759720X16687480","volume":"9","author":"V Sundararaghavan","year":"2017","unstructured":"Sundararaghavan V, Mazur MM, Evans B, Liu J, Ebraheim NA (2017) Diabetes and bone health: latest evidence and clinical implications. Ther Adv Musculoskelet Dis 9(3):67\u201374","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"8","key":"1284_CR30","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.1073\/pnas.1200797109","volume":"109","author":"W Wei","year":"2012","unstructured":"Wei W, Dutchak PA, Wang X, Ding X, Wang X, Bookout AL et al (2012) Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor gamma. Proc Natl Acad Sci U S A 109(8):3143\u20133148","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"1284_CR31","doi-asserted-by":"publisher","first-page":"845","DOI":"10.2337\/dc07-2270","volume":"31","author":"SE Kahn","year":"2008","unstructured":"Kahn SE, Zinman B, Lachin JM, Haffner SM, Herman WH, Holman RR et al (2008) Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 31(5):845\u2013851","journal-title":"Diabetes Care"},{"issue":"4","key":"1284_CR32","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1002\/jbmr.2936","volume":"32","author":"X Li","year":"2017","unstructured":"Li X, Stanislaus S, Asuncion F, Niu QT, Chinookoswong N, Villasenor K et al (2017) FGF21 is not a major mediator for bone homeostasis or metabolic actions of PPARalpha and PPARgamma agonists. J Bone Miner Res 32(4):834\u2013845","journal-title":"J Bone Miner Res"},{"issue":"4","key":"1284_CR33","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1007\/s00198-012-2066-y","volume":"24","author":"ME Danielson","year":"2013","unstructured":"Danielson ME, Beck TJ, Karlamangla AS, Greendale GA, Atkinson EJ, Lian Y et al (2013) A comparison of DXA and CT based methods for estimating the strength of the femoral neck in post-menopausal women. Osteoporos Int 24(4):1379\u20131388","journal-title":"Osteoporos Int"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-024-01284-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00223-024-01284-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-024-01284-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T06:04:17Z","timestamp":1730527457000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00223-024-01284-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,28]]},"references-count":33,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["1284"],"URL":"https:\/\/doi.org\/10.1007\/s00223-024-01284-3","relation":{},"ISSN":["1432-0827"],"issn-type":[{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,28]]},"assertion":[{"value":"14 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Eunji Kim, Amelia Elizabeth Moore, Dwight Dulnoan, Geeta n Hampson have no competing interests to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval for the initial study was obtained from the South East London Research and Ethics Committee, UK. All patients gave informed consent and agreed that their aliquoted samples which were not used in the initial study could be stored and used in future ethically approved studies. Ethical approval for using the stored biological samples was obtained from the Human Research Authority (HRA) UK and the Health and Care Research Committee, Wales, UK. The current study was carried out in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}